Clinical Trial Update: An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 trial evaluating Vesemnogene Lantuparvovec for spinal muscular atrophy; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Vesemnogene Lantuparvovec

Snippet

Sponsor: Lantu Biopharma | Conditions: Spinal Muscular Atrophy | Phase 1, Phase 2 | Status: RECRUITING